MindBio Therapeutics Engages Venture Liquidity Providers for Market-Making Services

MindBio Therapeutics Corp., a biotechnology company focused on AI-driven voice analytics for drug and alcohol intoxication detection, has announced the appointment of Venture Liquidity Providers to provide market-making services for its common shares, subject to regulatory and final approvals. The engagement aims to maintain an orderly trading market for the company's shares, with the service to be conducted through W.D. Latimer Co. Ltd. in compliance with Canadian Securities Exchange policies. MindBio has agreed to pay $5,000 per month over a 12-month term for these services, with the arrangement being terminable at any time, while both parties operate at arm's length and VLP holds no direct or indirect interest in the company or its securities.

The market-making services are designed to enhance liquidity and trading stability for MindBio's shares, which trade on multiple exchanges including the Canadian Securities Exchange under the symbol MBIO, the Frankfurt exchange under WF6, and the OTCQB under MBQIF. This strategic move comes as the company continues to develop its enterprise platform for intoxication detection using voice analysis and artificial intelligence. The company's AI prediction model utilizes over 50 million data points to predict alcohol intoxication with what it describes as remarkable accuracy through voice analysis alone.

MindBio is developing an enterprise platform that includes Edge-AI kiosks integrating bespoke hardware and software for detecting drug and alcohol intoxication using human voice and artificial intelligence. The technology is targeted for deployment in various enterprise environments including the mining industry, aviation, construction, and law enforcement sectors. The company's latest news and updates relating to MBQIF are available in the company's newsroom at https://ibn.fm/MBQIF. The full press release regarding the market-making services can be viewed at https://ibn.fm/4evlA.

The engagement of market-making services represents a significant step for MindBio in supporting its public market presence and potentially improving trading conditions for investors. Market-making services typically involve maintaining bid and ask prices for securities and standing ready to buy or sell shares to facilitate trading. This can be particularly important for companies in the biotechnology sector, where research and development timelines can be lengthy and investor patience may be tested. By ensuring more consistent liquidity, MindBio aims to create a more stable trading environment that could benefit both the company and its shareholders.

BioMedWire, the platform that disseminated this announcement, is a specialized communications platform focusing on developments in biotechnology, biomedical sciences, and life sciences sectors. It is part of the Dynamic Brand Portfolio at IBN that provides various distribution services including wire solutions, article syndication to over 5,000 outlets, press release enhancement, social media distribution, and corporate communications solutions. More information about BioMedWire is available at https://www.BioMedWire.com, with full terms of use and disclaimers accessible at https://www.BioMedWire.com/Disclaimer.